Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months
Share
Why It Matters
Corvus tested a new medicine on people with a serious blood cancer, and it helped some of them feel better and live longer. When a company shares good test results like this, it's a sign their medicine might be worth watching, though many medicines still need more testing before they help lots of people.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.